Cáncer de mama metastásico: Caracterización de una cohorte según subtipos

• César Sánchez R ^[1] ; Francisco Acevedo C ^[1] ; Militza Petric G ^[1] ; Héctor Galindo A ^[1] ; Francisco Domínguez C ^[1] ; Augusto León R ^[1] ; Dravna Razmilic V ^[1] ; Carolina Ceballos ^[1] ; Fernando Espinoza ^[1] ; M. Elena Navarro O ^[1] ; David Oddó B ^[1] ; Mauricio Camus A ^[1]
  1. [1] Pontificia Universidad Católica de Chile

     Pontificia Universidad Católica de Chile

     Santiago, Chile

     
• Localización: Revista Médica de Chile, ISSN-e 0034-9887, Vol. 142, Nº. 4, 2014, págs. 428-435
• Idioma: español
• Títulos paralelos:
  • Survival of patients with metastatic breast cancer according to pathological types of tumors
• Enlaces
  • Texto completo
• Resumen

  • Background: The prognosis of breast cancer (BC) is in part determined by the stage at diagnosis and its pathological characteristics. Aim: To evaluate the association between survival of women with metastatic breast cancer and pathological features of the tumor. Patients and Methods: We obtained clinical and pathological data from patients diagnosed with a metastatic BC between 1999 and 2013. The expression of estrogen (ER) and progesterone (PR) receptors and human epidermal growth factor receptor 2 (HER2) was determined by immunohistochemistry. Clinicopathological subtypes were defined as: Luminal A: ER or PR positive, HER2 negative, histological grade (HG) 1 or 2; Luminal B: ER or PR positive, HER2 negative or positive or HG 3; triple negative (TN): ER, PR and HER2 negative, independent of the HG, positive HER2: ER, PR negative and HER2 positive, independent of HG. We analyzed survival based on these subtypes. Results: We identified 54 patients aged 24 to 85 years, with metastatic BC at diagnosis. Seventy five percent had luminal tumors; 19.6% HER2 positive and 7.8% were TN. In 61% of evaluable tumors, HG was classified as 3. The frequency of HER2 positive and high HG tumors was greater in these patients with metastatic BC than in a non-metastatic local BC cohort. Survival was higher among patients with Luminal tumors than in women with non-Luminal cancer (56.4 and 11.4 months, respectively, p = 0.04). Conclusions: Patients with metastatic BC at diagnosis often had HER2 positive tumors and high HG. As in other studies, ER positive tumors had a better survival.